Survey of various carbapenem-resistant mechanisms of Acinetobacter baumannii and Pseudomonas aeruginosa isolated from clinical samples in Iran

Leila Azimi 1, Fatemeh Fallah 1, Abdollah Karimi 1, Mehdi Shirdoust 1, Taher Azimi 2, Iraj Sedighi 3, Mohammad Rahbar 4, Shahnaz Armin 1*

1Pediatric Infections Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3Pediatric department, faculty of medicine, Hamadan University of Medical Sciences, Hamadan, Iran
4Department of Microbiology, Reference Health Laboratories Research Center, Ministry of Health and Medical Education, Tehran, Iran

ARTICLE INFO

Article type:
Original article

Article history:
Received: Dec 7, 2019
Accepted: Aug 23, 2020

Keywords:
Acinetobacter baumannii
Carbapenems
Drug resistance
Iran
Pseudomonas aeruginosa

ABSTRACT

Objective(s): Pseudomonas aeruginosa and Acinetobacter baumannii resist antibiotics by different intrinsic and acquired mechanisms. This study aims to define various carbapenem-resistant mechanisms of isolated P. aeruginosa and A. baumannii from nine different provinces of Iran.

Materials and Methods: In this cross-sectional study, all carbapenem-resistant P. aeruginosa and A. baumannii samples from nine provinces of Iran on a one-year time horizon were gathered. Modified Hodge Test (MHT) and Carba NP-Test were applied to the identification of producing-carbapenemase strains. The most important carbapenemase genes recognized by PCR and gene overexpression of the efflux pump were surveyed by efflux pump inhibitors (EPIs) and confirmed by Real-Time PCR.

Results: Twenty-one percent and 43.5% of P. aeruginosa and A. baumannii isolates were resistant to carbapenem, respectively. MHT and Carba NP tests identified 21% and 11% carbapenemase-producing strains in these Gram-negative bacteria, respectively. NDM-1 was the most prevalently detected carbapenemase in P. aeruginosa; OXA-51 and OXA-23 were the most significant genes in A. baumannii. EPIs identified active efflux pumps in 20% and 28% of P. aeruginosa and A. baumannii, respectively. Real-time PCR confirmed gene overexpression of efflux pumps in 54% and 30% of positive EPIs in P. aeruginosa and A. baumannii, respectively.

Conclusion: P. aeruginosa and A. baumannii may become multi-drug-resistant (MDR) and Extensively Drug-Resistant (XDR) strains and cause a high rate of mortality and morbidity. Thus, it is of necessity to prohibit the spread of antibiotic-resistant strains in hospitals.

Introduction

Carbapenems are broad-spectrum beta-lactam antibiotic agents. They are usually considered the last choice for antibiotic therapy, especially in combating Extended-Spectrum Beta-Lactamase (ESBL) producing microorganisms (1). Although some alternative antibiotics such as tigecycline and colistin can be used in case of carbapenem resistance, these are characterized by low effectiveness and/or high toxicity (1). The rate of carbapenem resistance to Gram-negative bacteria, especially in nosocomial pathogens such as P. aeruginosa and Acinetobacter baumannii, is high and increasing steadily (1-3). Nosocomial isolated P. aeruginosa and A. baumannii may be resistant to most of the available antibiotics and act as Multi-Drug Resistant (MDR) and Extensive Drug-Resistant (XDR) strains (3-5). The presence of carbapenem-resistant bacteria can be quite considerable because they enjoy the chance to shift to MDR strains commonly (1). P. aeruginosa and A. baumannii can become resistant to carbapenem through various mechanisms (2, 3, 6). The most important mechanism is the potential to produce carbapenemase because most of the carbapenemase genes can be found on the transferable genetic elements and they spread rapidly among bacteria (3, 5, 7). Different classes of carbapenemase can be detected in Gram-negative bacteria including Ambler classes A, B, and D β-lactamases (8). One of the inherent resistant mechanisms of carbapenem is the presence of active efflux pumps. It is important because it can cause cross-resistance to other antibiotic families (2, 9). Resistance to most of the available antibiotics in P. aeruginosa and A. baumannii can become a complex challenge for physicians due to the limited number of choices left for antibiotic therapy. This study is a multicenter research that aims to evaluate different mechanisms of carbapenem-resistant P. aeruginosa (CRPA) and A. baumannii (CRAB) through phenotypic and molecular techniques.

Materials and Methods

Setting and bacterial isolates

In this cross-sectional study, P. aeruginosa and A. baumannii strains were collected from nine provinces of Iran from September 2016 up to September 2017.

Antibiotic susceptibility testing

Carbapenem susceptibility was evaluated according to CLSI guidelines (10). P. aeruginosa ATCC 27853 was adopted as the control strain. All Carbapenems-resistant
strains were included in the study.

**Phenotypic screening of carbapenemase-producing strains**

Phenotypic screening of carbapenemase-producing strains was carried out by the Modified Hodge Test (MHT) (10) and CarbaAcineteto NP test according to CLSI guidelines (2016)(11).

**Modified Hodge Test (MHT)**

MHT was accomplished to identify carbapenemase-producing *A. baumannii* by using *E. coli* ATCC 25922 and etepenem disc (10 µg). Strains with cloverleaf images of inhibition zone were considered as carbapenemase-producing strains according to the CLSI guidelines (2016)(10).

**Carba NP test and CarbaAcineteto NP test**

The CarbaAcineteto NP test method has been described previously (11). In brief, one loop of a suspected strain was suspended in Tris-HCl mmol/l (5 M NaCl in CarbaAcineteto NP Test) as a lysis buffer from antibiogram wells with 100 µl of imipenem monohydrate solution (3 plates, vortexed for one min, and then incubated at room temperature for 5 min. Next, 30 µl of the supernatant was mixed in 96 wells with 100 µl of imipenem monohydrate solution (3 mg per ml) pH 7.8, phenol red solution, and 0.1 mmol/l ZnSO₄ (11).

**Molecular detection of carbapenemase genes**

The most prevalent carbapenemase genes were detected by conventional PCR. These genes included *VIM, IMP, NDM-1, SPM-1, KPC, GES, and OXA-48* in *P. aeruginosa* and *A. baumannii* and *OXA-23, OXA-40, OXA-24, OXA-58, and OXA-51* only in *A. baumannii*. Table 1 lists primers and Table 2 shows the previously described PCR conditions (12-18).

**Phenotypic screening of active efflux pumps**

**Treatment of the efflux pump by inhibitor**

Phenotypic discovery of active efflux pumps was facilitated by detecting Minimum Inhibitory Concentration (MIC) of imipenem ranging between 2-256 µg/ml with and without Cya-nide 3-Chlorophenyldrazone (CCCP) as an EPI. The final concentration of CCCP (C2759 Sigma-Aldrich, France) was 25 µg/ml, simultaneously (19). The positive condition for the presence of active efflux pumps in the isolates was, at least, the 4-fold reduction of MIC in the presence of CCCP. *A. baumannii* ATCC 19606 was used as the control strain.

**Relative gene expression by real-time PCR**

RNA extraction was carried out by the Thermo RNA extraction kit (cat. No. K0732) according to the manual’s instructions.

We used an RNeasy Mini Kit with 1 hr on-column DNase digestion (Qiagen NV, Venlo, The Netherlands) for purification of total RNA. Total RNA was quantified using a spectrophotometer (WPA Biowave II Nanospectrophotometer, USA) and ratio of absorbance at 260 nm vs 280 nm was used to assess RNA purity. Moreover, extracted RNA was screened on a 3% agarose gel.

At the next step, cDNA synthesis was executed by the Thermo kit (cat. No. K1622). Finally, the gene overexpression of MexX, MexC, and MexA in *P. aeruginosa* and of *adeB* in *A. baumannii* from RND-type efflux systems, involved in carbapenem resistance, was prepared. 16s rRNA was used as a house-keeping gene and *P. aeruginosa* ATCC 27853 and *A. baumannii* ATCC 19606 were considered as reference strains. The primers are shown in Table 1. Gene overexpression was calculated by the 2-ΔΔCT formula (20).

**Y=T or C; D=A or G or T**

**Y=T or C; D=A or G or T**

**Y=T or C; D=A or G or T**

Table 1. Primers used in this study for detection of resistance genes among *P. aeruginosa* and *A. baumannii* isolates.

| Gene   | Primer sequence 1 (F) | Primer sequence 2 (R) | MIC product size (bp) | Tm (°C) | Reference |
|--------|-----------------------|-----------------------|-----------------------|---------|-----------|
| ipp-R  | GATGTCCTGGTCTGATGTC  | CTGTCGTCTGATGTCGTC   | 406                   | 57.58   |           |
| per-F  | GCTTGGATCTGCTAGCAAG  | CGCTGCTGCTAGCAAGCA   | 371                   | 57.69   |           |
| per-R  | TGCTGATGCTGCTAGCAAG  | CGCTGCTGCTAGCAAGCA   | 57.54                 |         |           |
| esp-F  | GATGTCCTGGTCTGATGTC  | CTGTCGTCTGATGTCGTC   | 390                   | 55.61   |           |
| esp-R  | CGATGTCCTGCTGCTAGCA  | CGATGTCCTGCTGCTAGCA  | 59.54                 |         |           |
| imp-F  | TTGACACTGATTGATTGAT  | GGATGTTGATTGATTGATT  | 139                   | 40.56   |           |
| imp-R  | GATGTCCTGGTCTGATGTC  | CTGTCGTCTGATGTCGTC   | 51.92                 |         |           |
| NDRM-1-F | CGGCTGCCGAGCTGAGCA  | GGCTGCCGAGCTGAGCA   | 129                   | 64.73   |           |
| NDRM-1-R | CTGATGCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 60.11                 |         |           |
| SPM-2-F  | GGGTTGCTGCTGCTAGCA  | GGGTTGCTGCTGCTAGCA  | 447                   | 60.49   |           |
| SPM-2-R  | GGGTTGCTGCTGCTAGCA  | GGGTTGCTGCTGCTAGCA  | 63.98                 |         |           |
| spo-48-F | CGAAGATTTTGACCAGCAAG  | TAAATGTTCCATTTCACGCAT | 389                   | 63.23   |           |
| spo-48-R  | CTGTCGTCTGATGTCGTC  | CGCTGCTGCTAGCAAGCA   | 62.30                 |         |           |
| spo-23-F  | GATGTCCTGGTCTGATGTC  | CTGTCGTCTGATGTCGTC   | 55.86                 |         |           |
| spo-23-R  | CGATGTCCTGCTGCTAGCA  | CGATGTCCTGCTGCTAGCA  | 56.69                 |         |           |
| spo-40-F  | GGATGTTGATTGATTGATT  | CGCTGCTGCTAGCAAGCA   | 56.44                 |         |           |
| spo-40-R  | CGGATGTCCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 68.57                 |         |           |
| spo-24-F  | GGGTTGCTGCTGCTAGCA  | GGGTTGCTGCTGCTAGCA  | 57.39                 |         |           |
| spo-24-R  | ACGATGTCCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 57.41                 |         |           |
| spo-58-F  | ACGATGTCCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 58.45                 |         |           |
| spo-58-R  | GGCTGCCGAGCTGAGCA   | GGCTGCCGAGCTGAGCA   | 59.60                 |         |           |
| spo-52-F  | TAAATGTTCCATTTCACGCAT | GGGTTGCTGCTGCTAGCA  | 53.53                 |         |           |
| spo-52-R  | TGGATGCTGCTGCTAGCA  | TGGATGCTGCTGCTAGCA  | 56.61                 |         |           |
| adeB-F  | AAGGGACGGGCTTCTGCTAGT  | GATGTCCTGCTGCTAGCA  | 84                   | 60.32   |           |
| adeB-R  | CTGATGCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 58.36                 |         |           |
| 16sRNA-F  | CGATGTCCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 61.31                 |         |           |
| 16sRNA-R  | CGATGTCCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 57.67                 |         |           |
| Mex-F  | TGGATGCTGCTGCTAGCA  | AAGGGACGGGCTTCTGCTAGT | 326                   | 69.22   |           |
| Mex-R  | CTGATGCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 69.70                 |         |           |
| MexCR-F | CGATGTCCTGCTGCTAGCA  | CGATGTCCTGCTGCTAGCA  | 316                   | 70.12   |           |
| MexCR-R | CTGATGCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 70.62                 |         |           |
| MexCR-T | CTGATGCTGCTGCTAGCA  | CTGATGCTGCTGCTAGCA  | 45.93                 |         |           |

| Cycle | Temperature (°C) | Time | Number of cycles |
|-------|-----------------|------|------------------|
| Initial desaturation | 94 | 1-10 min | 1 |
| Denaturation | 94 | 30-45 sec | 30-40 |
| Annealing | 54-63° | 30-45 sec | 30-40 |
| Extension | 72 | 30 sec | 1-1 min |
| Final extension | 72 | 1-7 min | 1 |

*Based on each gene*
Azimi et al. Inherent and acquired carbapenem resistance mechanisms

Table 3. Results of MHT of carbapenem-resistant strains

| Bacteria       | MHT positive (%) | Carba NP positive (%) | MHT & Carba NP negative (%) |
|----------------|------------------|-----------------------|-----------------------------|
| *P. aeruginosa*| 21 (15)          | 17 (12)               | 182 (73)                    |
| *A. baumannii* | 87 (23)          | 38 (10)               | 258 (67)                    |

MHT: Modified Hodge Test

Statistical analysis

SPSS 22.0 statistical software (IBM Corp., Armonk, USA) was utilized to conduct data analysis. Mean, Confidence Interval (CI), etc. were analyzed by the Explore test in SPSS version 22.0 software. Sensitivity and specificity of phenotypic methods were calculated through the following formula (21):

Sensitivity = (a/(a+c)) × 100
Specificity = (d/(b+d)) × 100
Positive predictive value (PPV) = (a/(a+b)) × 100
Negative predictive value (NPV) = (d/(c+d)) × 100

Results

In this cross-sectional study, 675 *P. aeruginosa* and 869 *A. baumannii* remained definite throughout the study, and 140 (20.7%) and 383 (44%) of them, respectively, were resistant to carbapenem. The results of MHT and Carba NP tests used to identify carbapenemase-producing strains are shown in Table 3.

According to the results from molecular detection of carbapenemase by PCR, NDM-1 was the most prevalent enzyme in CRPA and OXA-51 and OXA-23 were the most prevalent genes in CRAB. SPM-1, KPC, GES, and OXA-58 were not observed in any of the strains (Figures 1 and 2).

Figure 1. PCR based identification of the NDM-1, imp, vim, and oxa-48 genes, using species primer pairs in *P. aeruginosa* and *A. baumannii* isolates

M: marker 50bp (SMO321, Fermantas). 1: positive NDM-1: 129bp, 2: positive imp: 139bp, 3: positive vim: 390bp, 4: positive oxa-48: 389 bp, and 5: negative control

Table 5. Number (%) of detected carbapenemase genes in carbapenem-resistant *Acinetobacter baumannii*

| Bacteria       | VIM    | IMP    | NDM-1  | SPM-1  | KPC    | GES    | OXA-48  | OXA-23  | OXA-51  | OXA-40  | OXA-24  | OXA-58  |
|----------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| *A. baumannii* | 7 (2%) | 1 (0.3%)| 36 (9.4%) | _      | _      | _      | _      | 59 (15.4%) | 290 (76.5%) | 383 (91.6%) | 85 (22.3%) | 252 (65.3%) | _      |

Table 6. Evaluation of MHT and Carba NP test in detecting carbapenemase

| Bacteria       | MHT (%) | Carba NP test (%) |
|----------------|---------|-------------------|
|                | Sensitivity | Specificity | PPV | NPV* | Accuracy | Sensitivity | Specificity | PPV | NPV* | Accuracy |
| *P. aeruginosa*| 7        | 83                | 5   | 89   | 76       | 23          | 92        | 23  | 92   | 9        |
| *A. baumannii* | 20       | 89                | 98  | 3    | 21       | 14          | 89        | 97  | 3    | 16       |

* Positive predictive value; ** Negative predictive value; MH: Modified Hodge Test

Figure 2. PCR based identification of the oxa-23, oxa-24, oxa-51 and oxa-40 genes, using species primer pairs in *P. aeruginosa* and *A. baumannii* isolates

M: marker 100bp (SM0321, Fermantas). 1: negative control 2- 5: positive oxa-23: 1058 bp, 6: 7: positive oxa-24: 246 bp, 8:9: positive oxa-40: 846 bp, 10, 11: positive oxa-51: 353 bp

Table 4. Number (%) of detected carbapenemase genes in carbapenem-resistant *Pseudomonas aeruginosa*

| Bacteria       | VIM | IMP | NDM-1 | SPM-1 | KPC | GES | OXA-48 | OXA-23 | OXA-51 | OXA-40 | OXA-24 | OXA-58 |
|----------------|-----|-----|-------|-------|-----|-----|--------|--------|--------|--------|--------|--------|--------|
| *P. aeruginosa*| 9 (6) | 10 (7) | _     | _     | _    | _   | _      | _      | _      | _      | _      | _      |

Figure 3. Results of gene expression of each efflux pump in Efflux Pump Inhibitors (EPIs) positive *Pseudomonas aeruginosa*

*MexX* was 8.34 & MexC was 7.98 with CI 95%; 1 to 17.15. The mean gene expression of MexA was 67.91 with CI 95%: 16.33 to 119.50. The mean gene expression of MexC was 85.32 with CI 95%: 22.3% to 252.35 with CI 95%. The mean gene expression of MexC was 65.8% with CI 95%: 24.6 to 252.35 with CI 95%.
gene expression of MexC was 2.73 with CI 95%: 1 to 5.7. As a common efflux pump, AdeB gene overexpression was detected in 32 (30%) positive EPI tests of *A. baumannii* with a mean gene expression of AdeB leveled at 9.81, CI 95%: 3.37 to 16.25.

**Discussion**

In recent decades, CRPA and CRAB have been two of the most critical nosocomial pathogens threatening public health and the World Health Organization has included them in a global priority pathogens list of antibiotic-resistant bacteria (2, 4, 5, 7). Rapid horizontal spread of plasmid-borne carbapenemase in these bacteria can be one of the reasons that there is large-scale spread of carbapenem-resistant bacteria. According to the results of the conducted antibiotic susceptibility testing, 21% of the collected *P. aeruginosa* isolates were resistant to carbapenem. A research group from Brazil worked on *P. aeruginosa* isolated from blood (22). Their results confirmed that 44% of the mentioned isolates were resistant to carbapenems (22). The frequency of CRPA in the Brazilian study is higher than that in our results; therefore, the sources of collected bacteria may justify this difference in frequency. Ghasemian et al. (2019) published a review article about the frequency of CRPA and analyzed 36 studies from Iran (23). They reported the detection of CRPA in 55% of the studied isolates (22). We had access to materials and methods (the same as those of other studies) at 10 lab centers and different sorts of clinical specimens. Thus, the discrepancy between our proposed results and those in other studies may correspond to different specimens, materials, and methods (22, 23).

Production of carbapenemase is one of the significantly responsible mechanisms. NDM-1 is the most frequent carbapenemase in CRPA, as confirmed by the results of PCR and sequencing in the current study. NDM-1 is found on the plasmid and can carry other antibiotic-resistant genes (24). Therefore, the prevalence and identification of NDM-1 positive strains are quite important and the top priority for control by the nosocomial infection committee of each hospital. The results of a published study revealed that NDM-1-producing *P. aeruginosa* was not detected in or reported from Iran (25). Hence, the detection of NDM-1-producing *P. aeruginosa* in the current study is a very alarming sign for the health care system and it needs a significant approach.

Some phenotypic tests have been proposed so far to detect carbapenemase-producing organisms. MHT and Carba NP tests are two challenging methods. In the current study, the sensitivity and specificity of MHT and Carba NP tests to detecting carbapenemase in both of the bacteria under study are low and reasonable, respectively. In addition, other studies reported acceptable specificity but low sensitivity for MHT (26-28).

Efflux pumps are the other important carbapenem-resistant mechanisms that can cause the appearance of MD R and XDR strains because they can reject a different family of antibiotics, simultaneously (9). In the current study, 20% of CRPA showed active efflux pumps by the EPIs method. The results obtained in other studies showed the role of active efflux pumps in 18% of CRPA by EPIs (2), similarly to our findings. The results of Real-Time PCR confirmed 54% gene overexpression of the Mex family of efflux pumps in EPIs positive CRPA in this study. However, Azimi et al. reported gene overexpression in the Mex family of efflux pumps in 100% CRPA with the CCCP positive test (29). They used different methods for detecting the MIC method and EPI, which may explain the dissimilar results.

In the current study, 44% of the collected *A. baumannii* were resistant to at least one member of the carbapenem class. El Kettani A et al. (2017) showed that 76% of *A. baumannii* isolated from blood cultures were resistant to carbapenem (30). In 2018, researchers reported that 80% of *A. baumannii* isolated from wound burn specimens were imipenem-resistant (31). In the above two studies, strains were isolated from blood culture (30) and wounds burn (31); however, the current study evaluated the *A. baumannii* isolated from different clinical samples. We believe that the source of collected specimens and the use of different antibiotic discs in the brand (from different companies) can justify the divergence of our results from those in other studies. The concentration of more than one carbapenemase was observed in 1% and 2% of *P. aeruginosa* and *A. baumannii*, respectively. In addition, gene overexpression of the efflux pump was combined with carbapenemase in 1% of *P. aeruginosa* and all *A. baumannii*.

According to reports of other researchers, NDM-1-producing bacterium is one of the threatening isolates, while we found that 9% of CRAB pathogens were NDM-1 positive. Unfortunately, these results should be disturbing for Iran’s health system. Obtained results show that OXA-51 and OXA-23 are the most prevalent carbapenemase in isolated *A. baumannii*, as confirmed by other studies (5, 17, 32). Another responsible resistance mechanism is the efflux pump. According to real-time PCR results from evaluating AdeB gene expression, 29% of CRAB pathogens use the efflux pump mechanism. In previously published studies, several researcher groups worked on CRAB’s efflux pump mechanism and reported similar results to the findings of the current study (33-35).

**Conclusion**

The existence of different antibiotic-resistant mechanisms of *P. aeruginosa* and *A. baumannii* can cause cross antibiotic resistance, lead to the appearance of MDR and/or strains, and make the treatment difficult. The increasing number of NDM-1-producing bacteria is a very serious problem to combat in terms of antibiotic resistance. Therefore, finding a way to inhibit efflux pumps is quite essential for controlling the cross-resistance and appearance of MDR strains of bacteria.

**Acknowledgment**

The research reported in this publication was supported by the Elite Researcher Grant Committee (award no. (940290)) from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran. The authors are grateful to the entire staff of the Pediatric Infectious Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

**Conflicts of Interest**

This manuscript does not have any conflicts of interest.

**References**

1. Amini A, Libarahimizadeh Namvar A. Antimicrobial resistance pattern and presence of beta-lactamase genes in *Pseudomonas*
aeruginosa strains isolated from hospitalized patients, Babol-Iran. J Med Bacteriol 2019;8:45-50.
2. Bijari A, Azimi L, Fallah F, Ardebili A, Lari ER, Lari AR. Involvement of the multidrug efflux pumps in beta-lactams resistant Pseudomonas aeruginosa clinical isolates collected from burn patients in Iran. Infect Disord Drugs Treat. 2016;16:172-177.
3. Lari AR, Azimi L, Soroush S, Taherilalani M. Low prevalence of metallo-beta-lactamase in Pseudomonas aeruginosa isolated from a tertiary burn care center in Tehran. Int J Immunopathol Pharmacol 2015;28:384-389.
4. Armin S, Fallah F, Azimi L, Samadi Kafil, Ghazvini K. Hanrzanzaninia et al: epidemiology and possible risk factors in Iran. Cell Mol Biol (NY) 2018;64:125-129.
5. Azimi L, Talebi M, Pourshafie MR, Owlia P, Rastegar Lari A. Characterization of carbapenemases in extensively drug resistance Acinetobacter baumannii in a burn care center in Iran. Int J Mol Cell Med 2015;4:46-53.
6. Mobasser P, Azimi L, Salehi M, Hosseini F, Fallah F. Multi-drug resistance profiles and expression of adeJ and abem in Acinetobacter baumannii collected from humans by Real-time PCR. J Med Bacteriol 2018;7:50-56.
7. Owlia P, Azimi L, Gholami A, Aghsari B, Lari AR. ESBL- and MBL-mediated resistance in Acinetobacter baumannii: a global threat to burn patients. Int J Infect Dis 2012;20:182-187.
8. Karbassiadeh V, Heidari L, Jafari K. Detection of OXA-type carbapenemase genes in Acinetobacter baumannii isolates from nosocomial infections in Isfahan hospitals, Iran. J Med Bacteriol 2015;4:31-36.
9. Nikaido H, Pagès JM. Broad-specificity efflux pumps and their role in multidrug resistance of gram-negative bacteria. FEMS Microbiol Rev 2012;36:340-363.
10. Clinical laboratory standards institute. Performance standards for antimicrobial susceptibility testing: nineteenth information supplement M100–S21. CLSI, Wayne, PA. 2016.
11. Dörter L, Poier L, Errera C, Nordmann P. CarbAcinetO NP test for rapid detection of carbapenemase-producing Acinetobacter spp. J Clin Microbiol 2014;52:2359-2364.
12. Azimi L, Rastegar Lari A, Talebi M, Ebrahimzadeh Namvar AM, Soleymanzadeh Moghadam S. Evaluation of phenotypic methods for detection of Klebsiella Pneumoniae carbapenem-producing K. Pneumoniae in Tehran. J Med Bacteriol 2013;2:26-31.
13. Georghiou G, Czobor I, Chirifou MC, Borcan E, Gihtá C, Banu Q, et al. Molecular screening of carbapenemase-producing gram-negative strains in Romanian intensive care units during a one year survey. J Med Microbiol 2014;63:1303-1310.
14. Lowings M, Ehlers MM, Dreyer AW, Kock MM. High prevalence of OXA-1-like enzymes in clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane region, South Africa – an update. BMC Infect Dis 2015;14:2-10.
15. Yamazaki Y, Funahita T, Yasuhara T, Sugano E, Uegajin K, Tahara S, et al. Molecular characterization of a carbapenemase-producing Enterobacter species and Klebsiella species outbreak in a Japanese university hospital. Showa Univ J Med Sci 2017;29:163-172.
16. Zhou H, Pi BR, Yang Q, Yu VS, Chen YG, Li LJ, et al. Evaluation of carbapenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. J Med Microbiol 2007;56:1076-1080.
17. Héritier C, Poier L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 2005;49:3198-3202.
18. Joshi PR, Acharya M, Kakshapati T, Leungtongkam U, Thummeepak R, Sithisaksil S. Co-existence of blaOXA-23 and blaNDM-1 genes of Acinetobacter baumannii isolated from Nepal: antimicrobial resistance and clinical significance. Antimicrob Resist Infection Control 2017;7:6-21.
19. Ardebilii A, Talebi M, Azimi L, Rastegar Lari A. Effect of efflux pump inhibitor carbonyl cyanide 3-chlorophenylhydrazone on the minimum inhibitory concentration of ciprofloxacin in Acinetobacter baumannii clinical isolates. Jundishapur J Microbiol 2014;7:6691.
20. Azimi L, Namvar AE, Jamali S, Lari AR, Bijari A, Lari AR. Relative expression of efflux pumps in multi drug resistant Pseudomonas aeruginosa. Roum Arch Microbiol Immunol 2015;74:86-90.
21. Hadianj D, Shoja S, Diene SM, Rolain JM. Dual infections of two carbapenem-producing Acinetobacter baumannii clinical strains isolated from the same blood culture sample of a patient in Iran. Antimicrob Resist Infect Control 2018;7:39-42.
22. Lowe M, Ehlers MM, Ismail E, Peirano G, Becker PJ, Pitout JDB, et al. Acinetobacter baumannii: epidemiological and beta-lactamase data from two tertiary academic hospitals in Tshwane, South Africa. Front Microbiol 2018;9:1280-1289.
23. Subramanian JY, Sundaram J. Occurrence of bla genes encoding carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii from intensive care unit in a tertiary care hospital. J Lab Physicians 2018;10:208-213.
24. Ghanemian A, Salimian Rizi K, Rajabi Vardanjani H, Nojoomi F. Prevalence of clinically isolated metallo-beta-lactamase-producing Pseudomonas aeruginosa, coding genes, and possible risk factors in Iran. Iran J Pathol 2018;13:1-9.
25. Kuchibhotla T, Komatsu M, Yamasaki K, Nakamura T, Nishiho H, Nishi I, et al. Evaluation of the modified carbapenem inactivation method for the detection of carbapenemase-producing Enterobacteriaceae. J Infect Chemother 2018;24:262-266.
26. Davoudi-Monfared E, Khalili H. The threat of carbapenem-resistant gram-negative bacteria in a Middle East region. Infect Drug Resist 2018;17:1831-1880.
27. Azimi L, Talebi M, Owlia P, Pourshafie MR, Najafi M, Lari ER, et al. Tracing of false negative results in phenotypic methods for identification of carbapenemase by Real-time PCR. Gene 2016;576:166-170.
28. De Kiewit TR, Parks MD, Gillis RJ, Srikumar R, Ceri H, Poole K, et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2001;45:1761-1770.
29. El Kettani A, Maaloum F, Diawara I, Kafy K, Harrar N, Zerouali K, et al. Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochd hospital university, Casablanca, Iran. J Microbiol 2017;9:318-323.
30. Reza H. The frequency of multidrug-resistance and extensively drugresistant Acinetobacter baumannii in west of Iran. J Clin Microbiol Infect Dis 2018;8:1-10.
31. Sarikhan Z, Nazari R, Nateghi Rostami M. First report of Acinetobacter baumannii in west of Iran. J Clin Microbiol Infect Dis 2018;1:4-8.
32. Davoudi-Monfared E, Khalili H. The threat of carbapenem-resistant gram-negative bacteria in a Middle East region. Infect Drug Resist 2018;17:1831-1880.
33. El Kettani A, Maaloum F, Diawara I, Kafy K, Harrar N, Zerouali K, et al. Prevalence of Acinetobacter baumannii bacteremia in intensive care units of Ibn Rochd hospital university, Casablanca, Iran. J Microbiol 2017;9:318-323.
34. Dou Q, Zou M, Li J, Wang H, Hu Y, Liu W. AdeABC efflux pump and resistance of Acinetobacter baumannii against carbapenem. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2001;45:1761-1770.
35. Davoudi-Monfared E, Khalili H. The threat of carbapenem-resistant gram-negative bacteria in a Middle East region. Infect Drug Resist 2018;17:1831-1880.
36. Owrang M, Karimi A, Azimi L, Motaghi Nezhad R, Fallah F. Multidrug efflux pumps in tigecycline resistant Acinetobacter baumannii isolated from training hospitals in Tehran, Iran. Int J Pediatr 2018;6:8669-8674.
37. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:2065-2069.